Stockscreener 앱 받기
4.53
4.54%
-0.21
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright - MarketBeat
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Bitget
NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Nuvation Bio Inc. $NUVB is Aisling Capital Management LP's 4th Largest Position - MarketBeat
NUVB-WT Nuvation Bio NYSE down 27% pre-market after Q4: cash runway focus - Meyka
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks - TipRanks
Nuvation Bio (NUVB) awards stock options and RSUs to company officer - Stock Titan
Director Xiangmin Cui awarded 74,813 Nuvation Bio (NUVB) stock options - Stock Titan
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy - The Globe and Mail
Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings) - Benzinga
UBS Group Lowers Nuvation Bio (NYSE:NUVB) Price Target to $7.00 - MarketBeat
Nuvation Bio (NUVB) Analyst Rating Update: UBS Lowers Price Targ - GuruFocus
NUVB Crosses Below Key Moving Average Level - Nasdaq
Nuvation Bio (NYSE:NUVB) Shares Gap DownShould You Sell? - MarketBeat
NUVB: RBC Capital Raises Price Target for Nuvation Bio | NUVB St - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
UBS Adjusts Price Target on Nuvation Bio to $7 From $10, Maintains Neutral Rating - marketscreener.com
Nuvation Bio price target raised to $13 from $12 at RBC Capital - TipRanks
RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch By Investing.com - Investing.com UK
Nuvation Bio Posts Narrower FY25 Loss, Highlights IBTROZI Launch And Pipeline Progress; Stock Down - Nasdaq
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch - Investing.com
Nuvation Bio Q4 2025 Earnings Call Transcript - MarketBeat
Nuvation Bio Q4 Earnings Call Highlights - MarketBeat
Nuvation Bio reports Q4 EPS (11c), consensus (5c) - TipRanks
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips - Investing.com
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips By Investing.com - Investing.com South Africa
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Nuvation Bio Stock Is Dropping Despite Analyst Hikes - TipRanks
Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
Nuvation Bio Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:NUVB) 2026-03-02 - Seeking Alpha
Nuvation Bio (NUVB) launches IBTROZI and advances safusidenib, global partnerships - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Nuvation Bio Q4 Loss Narrows, Revenue Rises - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Posts Q4 Loss $-0.11, vs. FactSet Est of Loss of $-0.09 - marketscreener.com
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
NUVB: Rapid IBTROZI uptake, Eisai partnership, and improved net loss highlight Q4 2025 results - TradingView
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q4 Revenue $41.9M, vs. FactSet Est of $37.8M - marketscreener.com
Earnings Breakdown: Nuvation Bio Q4 - Benzinga
Nuvation Bio earnings in focus: Ibtrozi momentum faces test - Investing.com UK
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Finviz
Nuvation Bio Expands SIGMA Study to Phase 3 Trial - Intellectia AI
Nuvation Bio (NUVB) Is Up 8.6% After Expanding Safusidenib Into Phase 3 Registrational TrialHas The Bull Case Changed? - Yahoo Finance
11 Best Cancer Stocks to Invest In Now - Insider Monkey
A Look At Nuvation Bio’s Valuation As Safusidenib SIGMA Trial Advances To Phase 3 - Sahm
Nuvation Bio Inc (NUVB) Live Share Price, Invest From India - INDmoney
An Overview of Nuvation Bio's Earnings - Benzinga
Nuvation Bio Inc (NUVB) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Nuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial - Sahm
Where is Nuvation Bio Inc. (NUVB) Headed According to Wall Street Analysts? - Finviz
10 Small-Cap Stocks With Huge Growth Potential - Insider Monkey
Nuvation Bio to Participate in Upcoming Investor Conferences - The Malaysian Reserve
Nuvation Bio to Participate in Upcoming March 2026 Investor Conferences - BioSpace
3.96%
자본화:
|
볼륨(24시간):